Efficacy of tocilizumab therapy in severe COVID-19 pneumonia patients and determination of the prognostic factors affecting 30 days mortality

Creative Commons License

Delen L., Kasapoglu U. S., Gok A., Cagasar O., TETİK B., Oksuz E.

MARMARA MEDICAL JOURNAL, cilt.35, sa.3, ss.308-315, 2022 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 3
  • Basım Tarihi: 2022
  • Doi Numarası: 10.5472/marumj.1191126
  • Dergi Adı: MARMARA MEDICAL JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.308-315
  • Anahtar Kelimeler: SARS-CoV-2, COVID-19, Tocilizumab, Viral pneumonia, Cytokine storm, Prognostic factors, CYTOKINE STORM, PATHOGENESIS
  • İnönü Üniversitesi Adresli: Evet

Özet

Objective: In coronavirus disease - 19 (COVID-19) patients, cytokine storm develops due to the increase of pro-inflammatory cytokines. Tocilizumab (TU.), has been used in the treatment of COVID-19 patients and successful results have been obtained. The aim of this study was to determine the efficacy of TCZ and also investigate the prognostic factors affecting the success of treatment and mortality in COVID-19 patients treated with TCZ.